How to manage metformin (biguanide) in patients with hyperkalemia (elevated potassium levels) and impaired renal function?

From the Guidelines

Metformin should be discontinued in patients with an estimated glomerular filtration rate (eGFR) less than 30 mL/min per 1.73 m² due to the increased risk of lactic acidosis, regardless of potassium levels. Managing metformin in patients with hyperkalemia and impaired renal function requires careful consideration of the potential risks and benefits. According to the KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease 1, metformin should not be initiated in patients with an eGFR less than 30 mL/min per 1.73 m², and it should be stopped if the eGFR falls below this threshold.

For patients with mild to moderate renal impairment (eGFR 30-59 ml/min/1.73m²), the dose of metformin should be adjusted based on renal function, with a maximum dose of 1000 mg twice daily for those with mild impairment (eGFR 45-59 ml/min/1.73m²) and a maximum dose of 500 mg twice daily for those with moderate impairment (eGFR 30-44 ml/min/1.73m²) 1. However, a more recent study published in The Lancet Diabetes and Endocrinology in 2021 2 suggests that metformin should be discontinued if the eGFR is less than 30 mL/min per 1.73 m², which aligns with the KDIGO guideline.

Key considerations for managing metformin in patients with hyperkalemia and impaired renal function include:

• Discontinuing metformin if eGFR falls below 30 ml/min/1.73m² due to increased risk of lactic acidosis
• Adjusting the dose of metformin based on renal function for patients with mild to moderate impairment
• Monitoring renal function and serum potassium levels regularly, with laboratory checks recommended every 1-3 months depending on baseline values and stability
• Considering alternative glucose-lowering medications like DPP-4 inhibitors, GLP-1 receptor agonists, or insulin for patients with significant renal impairment or hyperkalemia.

It is essential to prioritize the patient's safety and adjust the treatment plan accordingly, taking into account the potential risks of lactic acidosis and the need for careful monitoring of renal function and serum potassium levels 2.

From the FDA Drug Label

Metformin hydrochloride tablets are contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m 2. In patients taking metformin hydrochloride tablets whose eGFR later falls below 45 mL/min/1.73 m 2, assess the benefit risk of continuing therapy. Discontinue metformin hydrochloride tablets if the patient's eGFR later falls below 30 mL/minute/1.73 m 2

The FDA drug label does not directly address stopping metformin due to elevated potassium levels. However, it does provide guidance on managing metformin in patients with impaired renal function, which can be a contributing factor to hyperkalemia.

• Key points:
  • Assess renal function prior to initiation of metformin and periodically thereafter.
  • Discontinue metformin if the patient's eGFR falls below 30 mL/minute/1.73 m 2.
  • In patients with eGFR between 30 to 45 mL/min/1.73 m 2, assess the benefit and risk of continuing therapy.
• Clinical decision: In the absence of direct guidance on managing metformin with elevated potassium levels, a conservative approach would be to monitor renal function and potassium levels closely, and consider discontinuing metformin if the patient's eGFR falls below 45 mL/min/1.73 m 2 or if hyperkalemia worsens 3, 3.

From the Research

Managing Metformin in Patients with Hyperkalemia and Impaired Renal Function

• Metformin is a widely prescribed oral anti-diabetic agent for the treatment of type 2 diabetes mellitus (DM2) 4.
• However, metformin can accumulate in patients with acute kidney injury (AKI) or chronic kidney disease (CKD), leading to potentially life-threatening complications such as metformin-associated lactic acidosis (MALA) and severe hyperkalemia 4, 5.
• The risk of lactic acidosis associated with metformin use in individuals with impaired kidney function is a concern, but the overall incidence of lactic acidosis in metformin users is relatively low, varying from approximately 3 per 100,000 person-years to 10 per 100,000 person-years 6.
• Patients with diabetes and impaired renal function are at greatest risk for hyperkalemia, and the use of metformin in these patients requires careful consideration of the potential risks and benefits 7, 8.

Considerations for Metformin Use in Patients with Hyperkalemia and Impaired Renal Function

• The decision to stop metformin in patients with elevated potassium levels and impaired renal function should be based on individual patient factors, including the severity of hyperkalemia, the degree of renal impairment, and the presence of other risk factors for lactic acidosis 4, 6.
• Available evidence supports cautious expansion of metformin use in patients with mild to moderate chronic kidney disease, as defined by estimated glomerular filtration rate, with appropriate dosage reductions and careful follow-up of kidney function 6, 8.
• However, in patients with severe hyperkalemia and impaired renal function, the risks of metformin use may outweigh the benefits, and alternative treatments should be considered 4, 5.

Monitoring and Management of Metformin-Associated Hyperkalemia and Lactic Acidosis

• Patients taking metformin should be monitored regularly for signs and symptoms of hyperkalemia and lactic acidosis, including nausea, vomiting, lethargy, and diarrhea 4, 5.
• In cases of suspected metformin-associated lactic acidosis, metformin should be discontinued promptly, and patients should be treated with supportive care, including infusion of isotonic saline solutions, mild alkalinizing solutions, and low-dose regular insulin 4, 5.
• The use of newer treatments for hyperkalemia, such as sodium zirconium cyclosilicate, may also be considered in patients with metformin-associated hyperkalemia 7.